CYRX vs LINE
CYRX: Cryoport is the leading provider of end-to-end temperature-controlled supply chain solutions specifically built for cell and gene therapies, from preclinical development through global commercialization. LINE: The world's largest global temperature-controlled warehouse REIT, providing end-to-end supply chain solutions for the food and perishable goods industry across 501 facilities.
Side-by-side fundamentals
| Metric | CYRX | LINE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $16.42 | $43.19 | |
| Market cap as of 2026-07-23 | $838M | $9.9B | |
| P/E as of 2026-07-23 | 11.02 | n/a | |
| Net margin as of 2026-07-23 | +41.6% | -2.7% | CYRX higher |
| Gross margin as of 2026-07-23 | +47.2% | +32.1% | CYRX higher |
| Operating margin as of 2026-07-23 | -21.4% | +3.0% | LINE higher |
| ROE as of 2026-07-23 | +15.0% | -1.8% | CYRX higher |
| ROA as of 2026-07-23 | +9.9% | -0.8% | CYRX higher |
| Debt / equity as of 2026-07-23 | 0.38 | 0.93 | CYRX lower |
| Revenue growth (YoY) as of 2026-07-23 | -14.8% | +1.1% | LINE higher |
| Revenue CAGR (3y) SEC XBRL | -9.4% | +0.1% | LINE higher |
| Dividend yield as of 2026-07-23 | n/a | +4.9% | |
| Dividend streak (yrs) SEC XBRL | n/a | 3 | |
| Beta as of 2026-07-23 | 1.89 | 1.37 | |
| 1-year return as of 2026-07-22 close | +121.0% | +1.9% | CYRX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.